MedTrace Logo

Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults

NCT02051335 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2017-02-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether scopolamine-induced cognitive impairment is attenuated by the administration of roflumilast in combination with donepezil.

Conditions

Interventions

DRUG

Roflumilast

Roflumilast tablets

DRUG

Roflumilast placebo

Roflumilast placebo-matching tablets

DRUG

Donepezil

Donepezil overencapsulated tablets

DRUG

Donepezil placebo

Donepezil placebo-matching overencapsulated tablets

DRUG

Scopolamine

Scopolamine subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca AstraZeneca · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02051335 on ClinicalTrials.gov